For patients with highly malignant gynecological tumors that are prone to recurrence, for patients of advanced age and poor health, for patients who are resistant to chemotherapy and cannot find effective drugs, and for patients who have difficulty with surgery and radiotherapy at advanced stages, is there any other way to control the disease and prolong life? Yes, that is biotherapy. What is Biotherapy? Biotherapy usually refers to the method of inhibiting or stopping tumor growth by mobilizing the body’s defense mechanism or regulating the body’s biological response through the action of biological agents. Biotherapy, as an important adjuvant therapy, is a kind of therapy to stabilize and balance the internal environment of the body by regulating the defense function of the body and inhibiting or destroying tumor cells with the help of bioengineering method. It is a real supportive therapy. It is the fourth major tumor treatment mode other than surgery, chemotherapy and radiotherapy. It is the future and hope for real cure of malignant tumor. What are the advantages of biological therapy? 1. The side effects are so mild that almost all patients can easily bear them. 2. It can be used synergistically with surgery and radiotherapy, which can not only reduce the toxic side effects of various treatments, but also play a fundamental role in increasing the effectiveness. 3.It can effectively stimulate the body to produce anti-tumor immune response, and its safety and feasibility have been confirmed, with satisfactory anti-tumor effect, which can effectively prolong the survival time of post-surgery patients and improve their quality of life. 4.Giving biological therapy after surgery can help to remove the residual tumor cells in the body and has certain advantages in preventing recurrence and metastasis. Our department has been exploring the use of biological therapy to control tumors for nearly 5 years and has received many unexpected results. Our hospital has the most advanced biotherapy research base in China, and the biotherapy programs that can be applied to treat gynecological malignant tumors include: dendritic cell (DC) vaccine, CIK cell therapy, GM-CSF modified tumor vaccine, allogeneic hematopoietic stem cells combined with individual chemotherapy between relatives and semi-compatible. Case 1: Female patient, 55 years old, underwent tumor cell ablation for ovarian cancer in 2004, the pathology was plasmacytoma, 8 courses of chemotherapy were given after surgery, recurrence in 2007, the tumor was gradually resistant to chemotherapy until no sensitive chemotherapy drug could be found, CA-125 rose to 560 u/ml. After 3 courses of treatment, CA-125 dropped and stabilized at about 100 u/ml, and the condition is stable now. Case 2: The patient was a 72-year-old female with clear cell carcinoma of the ovary and was in poor health. Her daughter’s hemizygous allogeneic hematopoietic stem cells were used in combination with individual chemotherapy, and no tumor recurrence has been seen for 3 years. A large number of clinical studies have proved that the supplementation of biological therapy in the treatment of ovarian cancer, endometrial cancer, cervical cancer and other gynecologic malignancies will bring great benefits to patients.